Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298246 | 1.00 | MAPT (0.50) | MAPTMEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL1297532 | 0.91 | PPM1B (0.46) | MAPTMEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL1196597 | 0.91 | MEN1 (0.45) | MAPTMEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL16175867 | 0.91 | GAA (0.50) | MAPTMEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL28708961 | 0.91 | PPM1B (0.46) | MAPTMEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL28475951 | 0.91 | PPM1B (0.46) | MAPTMEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL1169394 | 0.90 | MAPT (0.52) | MAPTMEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL17722440 | 0.88 | MEN1 (0.46) | MAPTMEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL14898977 | 0.88 | MEN1 (0.46) | MAPTMEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL16708922 | 0.88 | MEN1 (0.46) | MAPTMEN1KMT2AALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
| US-8182695-B2 | Bridged macrocyclic module compositions | WHITEFORD JEFFERY A (US) | 2012-05-22 | — | — | US | disclosed |
| US-8110679-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-7595368-B2 | Nanofilm compositions with polymeric components | COVALENT PARTNERS, LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090114596-A1 | NANOFILM AND MEMBRANE COMPOSITIONS | COVALENT PARTNERS LLC | 2009-05-07 | — | — | US | disclosed |
| US-20080290034-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2008-11-27 | — | — | US | disclosed |
| US-7432371-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS, LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | SBDS, NCL, INTS6 | MAPT 2666/4885MEN1 1259/4885KMT2A 3432/4885 |
| US-20080290034-A1 | Bridged macrocyclic module compositions | SBDS, NCL, INTS6 | MAPT 2515/4885MEN1 1223/4885KMT2A 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.